ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Novartis and Harvard form biomaterials pact

by Ryan Cross
March 26, 2018 | APPEARED IN VOLUME 96, ISSUE 13

 

Novartis is turning to biodegradable drug-delivery materials to boost its cancer vaccine programs. The Swiss company will work with implantable or injectable materials for cancer immunotherapy developed by scientists from Dana-Farber Cancer Institute and Harvard University’s Wyss Institute. Glenn Dranoff, Novartis’s head of immuno-oncology, says the materials are porous and filled with compounds that prime immune cells to target tumors. Dranoff previously worked on them while at Dana-Farber.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment